obesity

The European Commission (EC) has approved Rhythm Pharmaceuticals Inc's (NASDAQ: RYTM) Imcivree (setmelanotide) for obesity and the control of hunger. The approval covers obesity associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC),...

A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people.  The SPAC Deal: Gelesis announced a SPAC merger with Capstar Special Purpose Acquisition Corp (NYSE: CPSR). The deal values the company at a pro forma market...

9 Meters Biopharma Inc (NASDAQ: NMTR) has acquired global development rights to LOB-0136 (now known as NM-136) that targets glucose-dependent insulinotropic polypeptide (GIP) from Lobesity LLC. GIP is a hormone whose concentration increases significantly with overeating, leading to...

A team at Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Genetics Center has discovered mutations in the gene GPR75 that protect against obesity. Now, drug developers at Regeneron will use its VelocImmune technology, which generates antibodies from humanized mice, to find drugs...

Novo Nordisk A/S (NYSE: NVO) has gained U.S. approval for a once-weekly semaglutide 2.4 mg injection, dubbed Wegovy, for chronic weight management. The drug will be available to obese adults and certain overweight people and should be used in conjunction with diet and exercise, Novo...

Since 1975, global obesity levels have tripled. The most recent figures from the World Health Organization (WHO) found that over 1.9 billion adults were overweight and over 650 million were obese. These figures continue to rise despite attempts by governments and organizations to reverse the trends...

Novo Nordisk A/S (NYSE: NVO) is entering the Phase 3a study in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a trial with once-weekly subcutaneously administered semaglutide 2.4 mg. The company will launch the trial in the second...

By WeedMaps News' Maureen Meehan, provided exclusively to Benzinga Cannabis. While studies have shown that endocannabinoids naturally regulate a variety of physiological processes in our bodies, scientists are now finding that their function also includes sending a message from our gut to our...

Move over, American Eagle Outfitters (NYSE: AEO). There’s a new contender in clothing retail, and it’s gonna be big. Supersized, even. McDonald’s Corporation (NYSE: MCD) will launch its limited-edition apparel and merchandise line July 26 in honor of Global Delivery Day. “To...

Shares of EnteroMedics Inc (NASDAQ: ETRM), a nano-cap medical device company that uses neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, fell more than 28 percent early Tuesday morning, after soaring 30 percent the day before. The large sell-off in...

Meet Orexigen Therapeutics, Inc. (NASDAQ: OREX), a micro-cap biopharmaceutical company delivering one of the strongest stock market performances of 2017 so far. After losing almost 90 percent of its value over 2016, shares have recuperated more than 80 percent this year. Benzinga recently spoke...

SunTrust said it hasn't changed its benefit-risk profile for Zafgen Inc (NASDAQ: ZFGN)'s beloranib, citing that thromboembolic risks linger on the obesity drug that showed statistically and clinically significant improvements in body weight and glycemic control in a mid-stage trial. Related Link:...

Earlier this year, the journal Obesity published a study showing that marijuana users typically had a lower body mass index than those that refrain from using the drug. The figures supported claims that cannabis could be an effective treatment for sufferers of diabetes and suggested that GW...